News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022
News Daily News More Evidence Links Breast Arterial Calcification and CVD Risk L.A. McKeown March 15, 2022
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Daily News OMT Boosts Survival in Revascularized Patients at 10 Years Michael O'Riordan June 29, 2021
News Daily News In Female Veterans With Early ASCVD, Secondary Prevention Falls Short Michael O'Riordan April 21, 2021
News Daily News Pills for Erectile Dysfunction Linked to Fewer CVD Deaths Caitlin E. Cox March 24, 2021
News Daily News New Advanced Training Outlined for Future Vascular Medicine Specialists Michael O'Riordan January 21, 2021
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Daily News Postmenopausal Women See Added ASCVD Risk After Complicated Pregnancies Caitlin E. Cox September 18, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News PAD Patients Undertreated With Statins Despite Elevated CV Risk L.A. McKeown July 13, 2020
News Daily News Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease Michael O'Riordan March 13, 2020
News Conference News AHA 2019 LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE Michael O'Riordan November 13, 2019
News Conference News ESC 2019 CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients Shelley Wood September 03, 2019
News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019